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Abstract
We evaluated the need for transurethral biopsy at first follow-up after intravesical bacillus
Calmette-Guerin (BCG) therapy for superficial bladder cancer. The records of 84 patients with
superficial bladder cancer who received a 6- or 8-week course of BCG were reviewed. Patholog-
ical results before BCG, cystoscopic findings, urinary cytology, and biopsy results for evaluation
of BCG therapy were reviewed. All 19 patients with positive urinary cytology had evidence of
positive bladder biopsy results. Fifty-three of 54 patients (98.1%) with no visible recurrent tumor
and negative urinary cytology demonstrated negative pathological results on bladder biopsy. When
not found in conjunction with positive urinary cytology, erythematous mucosa on cystoscopy was
not an indicator of tumor recurrence or residual cancer. In conclusion, routine transurethral biopsy
of the bladder for evaluating the response to BCG intravesical therapy is not necessary in patients
who have no visible tumor on cystoscopy and negative urinary cytology./
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a or T1 and G3 superﬁ cial bladder cancer 
patients have a lifelong risk of progression and 
require particular attention [1,  2].  Bacillus 
Calmette-Guerin (BCG) is currently the most eﬀ ec-
tive intravesical therapy for managing this high-risk 
group,  including carcinoma in situ (CIS) [3,  4].  
Evaluations after BCG intravesical therapy are based 
on cystoscopic ﬁ ndings,  urinary cytology and routine 
transurethral bladder biopsy.  Because bladder biopsy 
is a more invasive and costly procedure than cystos-
copy and urinary cytology,  some urologists suggest 
omitting routine biopsy [5] while many urologist 
teams advocate biopsy in all patients following BCG 
therapy regardless of cystoscopic and/or cytologic 
T
We evaluated the need for transurethral biopsy at ﬁ rst follow-up after intravesical bacillus Calmette-
Guerin (BCG) therapy for superﬁ cial bladder cancer.  The records of 84 patients with superﬁ cial blad-
der cancer who received a 6- or 8-week course of BCG were reviewed.  Pathological results before 
BCG,  cystoscopic ﬁ ndings,  urinary cytology,  and biopsy results for evaluation of BCG therapy were 
reviewed.  All 19 patients with positive urinary cytology had evidence of positive bladder biopsy 
results.  Fifty-three of 54 patients (98.1ｵ) with no visible recurrent tumor and negative urinary cytol-
ogy demonstrated negative pathological results on bladder biopsy.  When not found in conjunction with 
positive urinary cytology,  erythematous mucosa on cystoscopy was not an indicator of tumor recur-
rence or residual cancer.  In conclusion,  routine transurethral biopsy of the bladder for evaluating the 
response to BCG intravesical therapy is not necessary in patients who have no visible tumor on cystos-
copy and negative urinary cytology.
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ﬁ ndings.  We reviewed the records of patients with 
high-grade superﬁ cial bladder cancer who received 
BCG therapy and assessed the need for routine trans-
urethral biopsy.
Materials and Methods
　 The records of 84 patients with superﬁ cial bladder 
cancer who received a 6- or 8-week course of BCG 
intravesical therapy consisting of intravesical adminis-
tration of 80 mg BCG in 40 ml saline solution were 
reviewed.
　 The criteria for patients receiving BCG therapy 
were 1) recurrence of tumors at least 3 times,  2) 
grade 3 pathological results,  or 3) CIS disease.  All 
84 patients underwent a bladder biopsy after 1ﾝ2 
months of BCG therapy.  The biopsy was performed 
on target lesions and with a routine random biopsy 
procedure [5].  Tumors were staged according to the 
TNM (tumor､ node､ metastases) staging system.  Post-
treatment cystoscopic ﬁ ndings and urinary cytology 
were analyzed: cystoscopic ﬁ ndings were documented 
as recurrent tumor,  erythematous mucosa,  or 
negative; urinary cytology was categorized as positive 
if malignant cells or suspicious cells were seen and 
negative if cells were described as negative or atypi-
cal.
Results
　 Eighty-four patients aged 48 to 87 years old 
(median 68) received BCG intravesical therapy.  
Thirty-seven patients had tumor recurrence 3 times or 
more,  57 had grade 3 pathological ﬁ ndings and 65 had 
Tis disease before therapy.  All 29 patients with 
unclear tumor size had a CIS lesion.  Table 1 shows 
the patient characteristics.
　 Table 2 shows the results of BCG therapy in the 
84 patients as evaluated by routine biopsy.  All 19 
patients with positive urinary cytology had evidence of 
positive bladder biopsy results.  Of the 65 cases with 
negative cytology,  53 patients demonstrated negative 
bladder biopsy results.  Seven of 13 patients (53.8ｵ) 
with erythematous bladder mucosa on cystoscopic ﬁ nd-
ings and 6 of 53 patients (11.3ｵ) with negative cysto-
scopic ﬁ ndings had positive biopsy results.  Fifty-three 
of 54 patients (98.1ｵ) with negative/erythematous 
mucosa on cystoscopic ﬁ ndings and negative urinary 
cytology had negative bladder biopsy results.  Overall,  
urine cytology for all patients had a sensitivity,  spec-
iﬁ city and positive predictive value of 61.3ｵ,  100ｵ 
and 1.00,  respectively.
　 Table 3 shows the results in patients with CIS 
lesions.  Urine cytology for patients with CIS had a 
sensitivity,  speciﬁ city and positive predictive value of 
83.3ｵ,  100ｵ and 1.00,  respectively.  We focused on 
the 43 patients with Tis disease before treatment and 
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Table 1　 Patient characteristics
No.  of patients
Tumor size (mm) ＜10 31
10～30 21
＞30  3
unclear 29
Grade G1  3
G2 24
G3 57
T stage Tis 36
Ta 21
T1 27
Table 3　 Results of Post-BCG biopsy (patients with CIS)
Cystoscopic 
ﬁ ndings
Positive cytology Negative cytology
Totalbiopsy 
positive
biopsy 
negative
biopsy 
positive
biopsy 
negative
Tumor 4 0 2 0 6
Erythema 6 0 0 5 11
Negative 5 0 1 42 48
Total 15 0 3 47 65
Table 2　 Results of Post-BCG biopsy (all patients)
Cystoscopic 
ﬁ ndings
Positive cytology Negative cytology
Totalbiopsy 
positive
biopsy 
negative
biopsy 
positive
biopsy 
negative
Tumor 7 0 11 0 18
Erythema 7 0 0 6 13
Negative 5 0 1 47 53
Total 19 0 12 53 84
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negative urinary cytology and negative cystoscopic 
ﬁ ndings after BCG therapy.  Only 1 patient (2.1ｵ) 
demonstrated G2,  Ta urothelial carcinoma (Fig.  1) by 
biopsy.
Discussion
　 Evaluations of response to BCG therapy are usu-
ally based on cystoscopic ﬁ ndings,  urinary cytology 
and histological results on routine biopsy.  Urinary 
cytology results in patients with high-grade cancer 
(especially CIS) are mostly positive,  and cystoscopic 
ﬁ ndings in such patients are commonly abnormal [6].  
Our criteria for BCG intravesical therapy were symp-
toms of high-risk superﬁ cial bladder cancer,  including 
frequent tumor recurrence,  grade 3 pathology,  and 
CIS histological ﬁ ndings.  All 19 of 19 patients 
(100ｵ) with positive cytology and/or positive cysto-
scopic ﬁ ndings had positive bladder biopsy results.  
Moreover,  there was no patient with positive cytology 
and negative biopsy results.  These results might indi-
cate that patients with positive urinary cytology after 
BCG could be deﬁ ned as treatment failure without 
routine bladder biopsy evaluation.
　 Dalbagni et al.  [7] were the ﬁ rst to question the 
need for routine biopsy after BCG treatment.  After 
reviewing the data,  they concluded that biopsy at 3 
months after BCG is not necessary if cystoscopy is 
normal or erythema is seen with normal urine cytol-
ogy.  Skemp et al.  [8] concluded that patients with 
negative cystoscopy and negative urine cytology can 
safely be spared transurethral bladder biopsy but rec-
ommended biopsy after BCG treatment for patients 
with CIS because suspicious cytology and abnormal 
cystoscopic ﬁ ndings were common.
　 Our results also demonstrated that 98ｵ of biop-
sies might be spared in patients with erythematous 
mucosa or negative ﬁ ndings on cystoscopy,  combined 
with negative cytology.  Only 1 patient demonstrated 
positive bladder biopsy results (G2 and Ta) with nega-
tive cystoscopic ﬁ ndings and negative urinary cytology.  
This histological result was not high grade or high 
stage including G3/CIS,  which is why urinary cytol-
ogy and cystoscopy might have been normal.  Such 
superﬁ cial low-grade,  very early-phase recurrent can-
cer would be detected several months later by fol-
low-up cystoscopy.
　 In summary,  routine transurethral biopsy of the 
bladder for evaluating the response to BCG intravesi-
cal therapy is not necessary in patients who have no 
visible tumor on cystoscopy and negative urinary 
cytology.
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Fig. 1　 Pathological ﬁ ndings of a patient with negative cytology and cystoscopy: A,  Before BCG: urothelial carcinoma,  G3,  Tis.; B,  
After BCG: urothelial carcinoma,  G2,  Ta.
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